Bristol Myers Squibb Company $BMY Stock Holdings Increased by Brookstone Capital Management

Key Points

• Brookstone Capital Management increased its Bristol Myers Squibb holdings by 28.8% in the first quarter, buying 35,588 additional shares and bringing its total position to 159,186 shares worth about $9.66 million.
• Bristol Myers Squibb reported better-than-expected first-quarter earnings, with EPS of $1.58 versus estimates of $1.42 and revenue of $11.49 billion, topping analyst forecasts.
• The company also announced a quarterly dividend of $0.63 per share, implying an annualized yield of 4.6%, while analysts currently have an average Hold rating and a $61.31 price target.

Brookstone Capital Management grew its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 28.8% in the first quarter, according to its most recent filing with the SEC. The firm owned 159,186 shares of the biopharmaceutical company's stock after acquiring an additional 35,588 shares during the quarter. Brookstone Capital Management's holdings in Bristol Myers Squibb were worth $9,655,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. waypoint wealth counsel bought a new position in shares of Bristol Myers Squibb during the 4th quarter valued at about $1,194,000. Life Cycle Investment Partners Ltd bought a new stake in shares of Bristol Myers Squibb in the 4th quarter worth approximately $34,406,000. Axxcess Wealth Management LLC boosted its holdings in Bristol Myers Squibb by 27.4% during the fourth quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company's stock worth $5,322,000 after buying an additional 21,196 shares in the last quarter. Daytona Street Capital LLC acquired a new position in Bristol Myers Squibb in the fourth quarter worth approximately $1,362,000. Finally, Pensionfund Sabic bought a new position in shares of Bristol Myers Squibb in the fourth quarter valued at $1,845,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.05% of the company's stock.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $54.66 on Tuesday. The stock's fifty day simple moving average is $57.25 and its 200-day simple moving average is $57.19. The company has a market capitalization of $111.62 billion, a price-to-earnings ratio of 15.35, a P/E/G ratio of 0.15 and a beta of 0.24. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping analysts' consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same period last year, the company posted $1.80 EPS. The business's quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts predict that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be paid a $0.63 dividend. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.6%. Bristol Myers Squibb's dividend payout ratio is 70.79%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on BMY. Citigroup reissued a "neutral" rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Guggenheim reaffirmed a "buy" rating and set a $72.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Royal Bank Of Canada started coverage on Bristol Myers Squibb in a research report on Tuesday, February 24th. They issued a "sector perform" rating and a $60.00 price target for the company. Wall Street Zen downgraded Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Saturday, June 6th. Finally, HSBC upped their price objective on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a "hold" rating in a research note on Tuesday, March 17th. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $61.31.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.